Skip to main content

Advertisement

Table 1 Clinical features of progressor and nonprogressor subgroup of EAA patients (according to data gained 12 months after diagnosis)

From: Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients

  Progressors Nonprogressors
Number of cases 14 34
Clinical features
Age (years) 64.6 ± 10.5 60.3 ± 10.9
Gender (M/F) 8/6 25/9
Smoking status (N/ES) 4/10 11/33
FVC (% e.v.) 79.1 ± 21.6 76.7 ± 22.8
DLco (% e.v.) 50.2 ± 21.8 51.8 ± 7.0
BALF Lym (%) 15.6 ± 14.7 36.6 ± 27.6
Treatment
Systemic corticosteroids 8 9
Supportive care only 6 0
Avoidance of inhalation antigen only 0 25
  1. M Male, F female, N Nonsmoker, ES Ever smoked, FVC Forced vital capacity, DLco Diffusion capacity for carbon monoxide, e.v. expected value
  2. Definition of progression: significant decline of lung function (10% drop of FVC and/or 15% drop of DLco) or acute exacerbation or death in a 12-month period